<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="In this perspective, we predominantly focus on the impact of" exact="SARS-CoV-2 infection" post="on ACE2 and dysregulation of the protective effect of"/>
 <result pre="alveolar angiotensin coagulopathy fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Severe acute respiratory syndrome" post="virus 2 (SARS-CoV-2) causes a respiratory disease that led"/>
 <result pre="(SARS-CoV-2) causes a respiratory disease that led to the fatal" exact="Coronavirus disease 2019" post="(COVID-19) pandemic. In late 2019, the SARS-CoV-2 outbreak was"/>
 <result pre="ACE2 receptor. How the known epidemiological and clinical manifestation of" exact="SARS-CoV-2 infection" post="may be explained by perturbations of physiological functions of"/>
 <result pre="critical for the understanding of the pathophysiological changes due to" exact="SARS-CoV-2 infection." post="Understanding of the molecular downstream effects of angiotensin (Ang)"/>
 <result pre="distress, myocardial injury, renal failure, and increased mortality due to" exact="SARS-CoV-2 infection" post="among the aging population and subjects with cardiovascular and"/>
 <result pre="is very important to note, especially in the context of" exact="SARS-CoV-2 infection," post="that besides the classical RAS/ACE mediated Ang II formation,"/>
 <result pre="assess the effect of ACE/ARB inhibitors (ClinicalTrials.gov Identifier: NCT04330300) on" exact="SARS-CoV-2 infection." post="If the alternative pathways in the formation of Ang"/>
 <result pre="ACE/ARB inhibitors play a role on the clinical course of" exact="SARS-CoV-2 infection." post="ACE2 acts as a ligand through its recently identified"/>
 <result pre="2020). However, pathological examination on autopsies have not investigated if" exact="SARS-CoV-2 infection" post="leads to total destruction of ACE2 receptors on the"/>
 <result pre="a randomized-controlled, open-label trial involving hospitalized adult patients with confirmed" exact="SARS-CoV-2 infection" post="showed no benefit of lopanavir (Cao et al., 2020)."/>
 <result pre="(GS5734) an inhibitor of RNA polymerase, originally developed to treat" exact="Ebola" post="infections, has in vitro activity against multiple RNA viruses,"/>
 <result pre="of remdesivir treatment alone or in conjunction with chloroquine in" exact="SARS-CoV-2 infection." post="Because hydroxychloroquine and chloroquine are considered inhibitors of endosomal"/>
 <result pre="are no randomized clinical trials to support their efficacy against" exact="SARS-CoV-2 infection." post="However, it is conceivable that their efficacy may vary"/>
 <result pre="of significant efficacy of antimalarial drugs in the treatment of" exact="SARS-CoV-2 infection" post="(Magagnoli et al., 2020). Corticosteroids are the most conventional"/>
 <result pre="lung epithelial cells and lung injury? (2) What effect(s) does" exact="SARS-CoV-2 infection" post="of lung epithelial cells/endothelial cells have on ACE2 expression"/>
 <result pre="(2013). Epidemiological, demographic, and clinical characteristics of 47 cases of" exact="Middle East respiratory syndrome" post="coronavirus disease from Saudi Arabia: a descriptive study. Lancet"/>
 <result pre="GuoY.-R.CaoQ.-D.HongZ.-S.TanY.-Y.ChenS.-D.JinH.-J.et al.. (2020). The origin, transmission and clinical therapies on" exact="coronavirus disease 2019" post="(COVID-19) outbreakâ€&quot;an update on the status. Military Med. Res.7,"/>
 <result pre="Science325, 1680â€&quot;1682. 10.1126/science.117566719779197 MenterT.HaslbauerJ. D.NienholdR.SavicS.HopferH.DeigendeschN.et al.. (2020). Post-mortem examination of" exact="COVID19" post="patients reveals diffuse alveolar damage with severe capillary congestion"/>
 <result pre="E.DaveyR. T.JrTshiani MbayaO.ProschanM.MukadiD.et al.. (2019). A randomized, controlled trial of" exact="Ebola" post="virus disease therapeutics. N. Engl. J. Med.381, 2293â€&quot;2303. 10.1056/NEJMoa191099331774950"/>
</results>
